Status:
COMPLETED
Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This trial is conducted in Europe. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir, insulin aspart and biphasic insulin a...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Insulin naive
- On OAD treatment for at least 4 months with metformin, a sulphonylurea or a combination
- Body Mass Index (BMI) below or equal to 40.0 kg/m2
- HbA1c (glycosylated haemoglobin): 7.0%-10% (both inclusive)
Exclusion
- Proliferative retinopathy
- Recurrent major hypoglycaemia
- Cardial problems
- Uncontrolled hypertension
- Impaired hepatic or renal function
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
708 Patients enrolled
Trial Details
Trial ID
NCT00184600
Start Date
November 1 2004
End Date
August 1 2009
Last Update
March 9 2017
Active Locations (63)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Dublin, Ireland, DUBLIN 15
2
Novo Nordisk Investigational Site
Dublin, Ireland, DUBLIN 7
3
Novo Nordisk Investigational Site
Dublin, Ireland, DUBLIN 8
4
Novo Nordisk Investigational Site
Galway, Ireland